Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Fiche publication
Date publication
novembre 2021
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent, Dr BERTAUT Aurélie, Pr COUTANT Charles, Dr LADOIRE Sylvain, Dr PEIGNAUX Karine, Dr DESMOULINS Isabelle, Dr ROUFFIAC-THOUANT Magali
Tous les auteurs :
Costaz H, Boulle D, Bertaut A, Rouffiac M, Beltjens F, Desmoulins I, Peignaux K, Ladoire S, Causeret S, Loustalot C, Padeano MM, Vincent L, Jankowski C, Arnould L, Coutant C
Lien Pubmed
Résumé
In the ACOSOG Z0011 trial, patients with primary breast cancer and 1-2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), despite a relevant rate of non-SLN metastases of 27%. According to the St Gallen expert consensus, and NCCN and ASCO clinical guidelines, ALND may be avoided in patients who meet all ACOSOG Z0011 inclusion criteria. This recommendation can also be extended to patients undergoing mastectomy, with 1 or 2 positive SLNs and an indication for chest wall radiation, in whom axillary radiotherapy can be proposed as an alternative to completion ALND. The aim of this study was to assess non-compliance with the NCCN and ASCO clinical guidelines and Z0011 criteria, namely the rate of performance of completion ALND when it was not recommended, and the rate of failure to perform completion ALND when recommended.
Mots clés
ACOSOG Z0011 Criteria, Breast cancer, Omitting axillary lymph node dissection, Sentinel lymph node
Référence
Bull Cancer. 2021 Nov 24;: